"Primary gain is ours as a society. Children having the opportunity to survive & thrive. Parents buying their children toys rather than having to choose a coffin for them. Because that’s what in reality it actually comes down to"
No it isn't, because even with the favourable outcome touted by SI, survival is still only 50% not the 100% you are implying, and even that outcome wasn't supported by the results of the two previous RCTs carried out by Osiris. And the p value of the open label trial depends on the hypothetical control group that is different depending on which study you choose to quote. The Osiris trials had favourable phase 2 trials as well that weren't confirmed in the phase 3 RCTs. That's what concerns SI and its the real reason he doesn't want to take the chance on a proper RCT. Really the aGVHD trial is of a size, design and quality you would expect from a phase 2 trial not a phase 3 pivotal trial for the FDA.
Just to remind you of the outcomes of the Osiris trials
https://www.evaluate.com/vantage/articles/news/osiris-left-clinging-niche-after-prochymal-failure
"Primary gain is ours as a society. Children having the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |